iShares U.S. Pharmaceuticals ETF·Financial Services

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund launched on May 1, 2006.

The iShares U.S. Pharmaceuticals ETF is led by Johnson & Johnson and Eli Lilly, two stocks whose earnings per share has nearly doubled over the last twelve months. Also in IHE's top ten holdings list are lower-growth but cheaper stocks like Pfizer. Overall, this balance results in a portfolio with very appealing growth-at-a-reasonable-price statistics. My calculations show that IHE's one-year estimated EPS growth rate is an exceptional 19.07%, while its forward P/E ratio sits at just 15.69x.

Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
The iShares U.S. Pharmaceuticals ETF seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector.
Financial Services
Asset Management
2006-05-05
0.69
Market Peers